Next Treatments
Back to Eczema

zelnecirnon

TypePill StageStopped · Phase 2 Why it stoppedSafety (severe liver injury) · RAPT Therapeutics · Nov 11, 2024“RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology, today announced it is terminating its zelnecirnon (RPT193) program.” (Based on Recent FDA Feedback RAPT Therapeutics Stops Zelnecirnon Program Following Clinical Hold Due to Single SAE of Severe Liver Injury) Latest updateFeb 25, 2026Phase 2 results posted · Trial stopped early

What stands out

New approach in eczema

  • Blocks CCR4, a homing receptor that helps guide immune cells
Derived from NCT05399368 · UniProt P51679 ·
11 US eczema labels (Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)
· This is a summary of public records for informational purposes only. It is not medical advice.

Results

Trial: NCT05399368
Stopped earlyStudy on clinical hold by FDAFrom the trial’s registry record
NCT05399368 · Ages 18–75 · This is a summary of trial data for informational purposes only. It is not medical advice.

History

Earliest recorded event: Aug 12, 2019. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

  • Feb 25, 2026Phase 2 results posted · Trial stopped earlyAn Efficacy and Safety Study of RPT193 in Adults With Atopic Dermatitis Why it stopped: Study on clinical hold by FDA. ClinicalTrials.gov NCT05399368
  • May 24, 2024Trial stopped earlyReason: Study on clinical hold by FDA. ClinicalTrials.gov NCT05399368
  • Apr 26, 2021Phase 1 trial completedA First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis ClinicalTrials.gov NCT04271514
  • Aug 12, 2019Phase 1 trial startedA First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis ClinicalTrials.gov NCT04271514

Sources

Trials